ֲý

Skip to Content on ֲý.org
You're location is
All Regions
ֲýr

Nationally Recognized Pediatric Care

Our hospitals are ranked by U.S. News & World Report as among the best in the nation in multi-specialties.

Find Out Why!
Closeup of a person holding a phone using the ֲý app.

We Make Health Care Easy With the ֲý App

Access communications, appointment and symptom tracking and more.

Online Bill Pay

Paying a bill online is easy and secure.

Learn More

Send a Free E-Card

Brighten the day of your loved one staying at one of our hospitals. 

Give It a Try
Young child posing with arms out like he is flying.

KidsHealth Library

Healthy living for parents, kids and teens.

Meet Our Team

Learn more about our physician researchers, clinicians and scientists.

Find a Researcher
# #

    Paul Fawcett, PhD

    Center Director/Principal Research Scientist

    ֲý Children's Hospital, Delaware 1600 Rockland Road Wilmington, DE 19803

    Biography

    B.S. biology , M.S. Biology , Ph.D. Chemistry/Biochemistry ( U Mass Lowell ) . Research on inflammatory and infectious diseases . Lyme , H.p . and JRA . Clinical assay development and use . Name and Position Title Paul T. Fawcett, Ph.D. Director Center for Clinical Diagnostics Education Institution and Location Degree Year(s) Field of Study University of Lowell B.S. 06/1977 Biology University of Massachusetts Lowell M.S. 06/1982 Biology University of Massachusetts Lowell Ph.D. 06/1986 Biochemistry/Chemistry Employment Principal Research Scientist Alfred I. duPont Hospital for Children, Wilmington, DE Director, Center for Clinical Diagnostics Head, Immunology Laboratories Head, Transplant Diagnostic Laboratory Director, Life Science Center Chair, Institutional Animal Care and Use Committee Selected Publications 1. Brescia AC, Rose CD, McCahan SM, Stetson T, Fawcett PT. “Differential gene expression profiles between fibroblast-like synoviocytes (FLS) from chronic and acute Lyme arthritis in the pediatric population,†American College of Rheumatology 70th Annual Scientific Meeting, Washington DC, November, 2006. Arthritis Rheum 54:S696, 2006. 2. Fawcett PT, Brescia AC, Cattalini M, Maduskuie VL, Rose CD. “Proteomic profile of synovial fluid of JIA patients with divergent outcomes after joint injection,†American College of Rheumatology 70th Annual Scientific Meeting, Washington DC, November, 2006. Arthritis Rheum 54:S168,2006. 3. Fawcett PT, Rose CD, Maduskuie VL, Stetson T, Brescia AC, Stella MK, Stanek PA. “In-Vitro production of inflammatory mediators by fibroblast-like stem cells from the synovial fluid of pediatric Lyme arthritis patients,†American College of Rheumatology 70th Annual Scientific Meeting, Washington DC, November, 2006. Arthritis Rheum 54:S168,2006. 4. Catalini M, Maduskuie V, Fawcett PT, Brescia AC, Rose CD. “Predicting duration of effect of joint injection among children with knee arthritis using cytokine profile in synovial fluid (sf) at injection time,†American College of Rheumatology 70th Annual Scientific Meeting, Washington DC, November, 2006. Arthritis Rheum 54:S326,2006. 5. Fawcett PT, Rose CD, Maduskuie VL, Brescia AC. “Comparison of inflammatory mediator profiles in synovial fluid from pediatric patients with acute and chronic Lyme arthritis.†American College of Rheumatology 71th Annual Scientific Meeting, Boston MA, November, 2007. Arthritis Rheum 56:S141,2007. 6. Brescia AC, Rose CD, McCahan SM, Stetson T, Fawcett, PT, “Gene expression profiles in an expanded cohort of pediatric Lyme arthritis. American College of Rheumatology 71st Annual Scientific Meeting, Boston, MA, November, 2007. Arthritis Rheum 56:S142, 2007. 7. Fawcett PT, Rose CD, Brescia AC, Maduskuie VL, Postell MM, Stetson T, Stanek PA. “Determination of in-vivo and in-vitro production of inflammatory mediators in pediatric patients with acute and chronic Lyme arthritis. American College of Rheumatology 71st Annual Scientific Meeting, Boston MA, November, 2007. Arthritis Rheum 56:S373, 2007. 8. Taddio A, Montico M, Fawcett PT, Maduskuie VL, Cattalini M, Ronfani L, Brescia AC, Rose CD. “Cytokine profile in synovial fluid (SF) as major duration predictor of intra-articular corticosteroid (IAC) injection in juvenile arthritis.†(podium presentation) American College of Rheumatology 71st Annual Scientific Meeting, Boston MA, November, 2007. Arthritis Rheum 56:S829, 2007. 9. AC Brescia, SM McCahan, T Stetson, CD Rose, PT Fawcett “Unique expression of bone morphogenetic protein 4 in fibroblast-like synoviocytes from children with oligoarticular JIA,†Keystone Pediatric Rheumatology Symposium, Keystone, CO, March, 2008 (podium), Pediatric Academic Societies' Annual meeting, Honolulu, HI, May, 2008. 10. AC Brescia, SM McCahan, T Stetson, CD Rose, PT Fawcett, “Fibroblast Transformation May Have a Role in Perpetuation of Synovitis in Antibiotic-Resistant Pediatric Lyme Arthritis†Keystone Pediatric Rheumatology Symposium, Keystone, CO, March 2008, Pediatric Academic Societies' Annual meeting, Honolulu, HI, May 2008 (podium). 11. M Catalini, V Maduskuie, PT Fawcett, AC Brescia, CD Rose, “Predicting duration of beneficial effect of joint injection among children with chronic arthritis by measuring biomarkers concentration in synovial fluid at the time of injection,†Clin. Exp Rheumatology 26(6):1153-60, 2008. 12. AC Brescia, CD Rose, PT Fawcett, “Prolonged Synovitis in Pediatric Lyme Arthritis cannot be predicted by clinical or laboratory parameters,†Clinical Rheumatology 28 (5):591-593, 2009.

    • Trends in Serum Cytokine Expression in Pediatric Skeletal Dysplasia; JBMR Plus; (2023).

    • Serial measurements of soluble interleukin 2 receptor levels (sIL2-R) in children with juvenile rheumatoid arthritis treated with oral methotrexate; Pediatrics; (2019).

    • Inflammatory Response of Pulmonary Artery Smooth Muscle Cells Exposed to Oxidative and Biophysical Stress; Inflammation; (2018).

    • The role of transforming growth factor β signaling in fibroblast-like synoviocytes from patients with oligoarticular juvenile idiopathic arthritis: Dysregulation of transforming growth factor β signaling, including overexpression of bone morphogenetic protein 4, may lead to a chondrocyte phenotype and may contribute to bony hypertrophy; Arthritis and Rheumatology; (2014).

    • Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo; BMC Cancer; (2011).

    • Prolonged synovitis in pediatric lyme arthritis cannot be predicted by clinical or laboratory parameters; Clinical Rheumatology; (2009).

    • Predicting duration of beneficial effect of joint injection among children with chronic arthritis by measuring biomarkers concentration in synovial fluid at the time of injection; Clinical and Experimental Rheumatology; (2008).

    • Cytokine load in prestorage leukoreduced PRBC transfusions in premature infants; Journal of Perinatology; (2005).

    • Comparison of PCR and clinical laboratory tests for diagnosing H. pylori infection in pediatric patients; BMC Microbiology; (2004).

    • Long-term effects of immunization with recombinant lipoprotein outer surface protein A on serologic test for Lyme disease; Clinical and Diagnostic Laboratory Immunology; (2004).

    • C<inf>6</inf> Test as an Indicator of Therapy Outcome for Patients with Localized or Disseminated Lyme Borreliosis; Journal of Clinical Microbiology; (2003).

    • In vitro assessment of antiborrelial activity of OspA vaccine sera; Clinical and Diagnostic Laboratory Immunology; (2002).

    • Growth of Helicobacter pylori in a long spiral form does not alterexpression of immunodominant proteins; BMC Microbiology; (2002).

    • Arthritis following recombinant outer surface protein A vaccination for lyme disease; Journal of Rheumatology; (2001).

    • Antibody response to IR<inf>6</inf>, a conserved immunodominant region of the VlsE lipoprotein, wanes rapidly after antibiotic treatment of Borrelia burgdorferi infection in experimental animals and in humans; Journal of Infectious Diseases; (2001).

    • Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis; Clinical and Diagnostic Laboratory Immunology; (2001).

    • Helicobacter pylori can be induced to assume the morphology of Helicobacter heilmannii; Journal of Clinical Microbiology; (1999).

    • Use of ELISA to measure antinuclear antibodies in children with juvenile rheumatoid arthritis; Journal of Rheumatology; (1999).

    • Comparison of immunodot and Western blot assays for diagnosing Lyme borreliosis; Clinical and Diagnostic Laboratory Immunology; (1998).

    • Correlation of seroreactivity with response to antibiotics in pediatric Lyme borreliosis; Clinical and Diagnostic Laboratory Immunology; (1997).

    • Residual serologic reactivity in children with resolved Lyme arthritis; Journal of Rheumatology; (1996).

    • Usefulness of soluble interleukin-2 receptor specificity [9]; Journal of Pediatrics; (1996).

    • Pharmacokinetics of teratogenic antibodies administered to rats; Teratology; (1995).

    • Soluble interleukin-2 receptor as a predictor of neonatal sepsis; The Journal of Pediatrics; (1995).

    • Comparative evaluation of adsorption with E. coli on ELISA tests for Lyme borreliosis; Journal of Rheumatology; (1995).

    • Pediatric Lyme Arthritis: Clinical Spectrum And Outcome; Journal of Pediatric Orthopaedics; (1994).

    • Serial measurements of soluble interleukin 2 receptor levels (sIL2-R) in children with juvenile rheumatoid arthritis treated with oral methotrexate; Annals of the Rheumatic Diseases; (1994).

    • The Overdiagnosis of Lyme Disease in Children Residing in an Endemic Area; Clinical Pediatrics; (1994).

    • Reinfection in paediatric Lyme borreliosis [2]; Annals of the Rheumatic Diseases; (1993).

    • Detection of antibodies to the recombinant P39 protein of Borrelia burgdorferi using enzyme immunoassay and immunoblotting; Journal of Rheumatology; (1993).

    • Examination of anti-neutrophil cytoplasmic antibodies in childhood inflammatory bowel disease; Journal of Pediatric Gastroenterology and Nutrition; (1993).

    • Serial measurement of soluble interleukin 2 receptor levels: An early indicator of treatment response for Lyme disease; Journal of Rheumatology; (1993).

    • Soluble interleukin‐2 receptor levels in infants with bronchopulmonary dysplasia; Pediatric Pulmonology; (1992).

    • Lyme neuroborreliosis: A potential cause of median neuropathy in a child and young adult; Infectious Diseases in Clinical Practice; (1992).

    • Frequency and specificity of antibodies that crossreact with Borrelia burgdorferi antigens; Journal of Rheumatology; (1992).

    • Adsorption with a soluble E. coli antigen fraction improves the specificity of ELISA tests for Lyme disease; Journal of Rheumatology; (1991).

    • Use of Western blot and enzyme-linked immunosorbent assays to assist in the diagnosis of Lyme disease; Pediatrics; (1991).

    • Induction of humoral manifestations of autoimmunity following intraperitoneal injection of complete freund's adjuvant in mice; Autoimmunity; (1990).

    • Suppression of malaria-induced autoimmunity by immunization with cryoglobulins; Cellular Immunology; (1989).

    • GLOVE POWDER AND HIV ELISA TESTS; The Lancet; (1989).

    • An adsorption procedure to increase the specificity of enzyme‐linked immunosorbent assays for lyme disease without decreasing sensitivity; Arthritis &amp; Rheumatism; (1989).

    • Androgen Suppression of Circulating Immune Complexes and Enhanced Survival in Murine Malaria; Proceedings of the Society for Experimental Biology and Medicine; (1982).